SSTR2 and nasopharyngeal carcinoma: SSTR2 has also been recognized as an imaging and treatment target in various neoplasms including neuroendocrine tumors such as paragangliomas and small cell lung carcinomas, but also other malignancies such as thyroid carcinomas, and EBV-driven and non-EBV-driven nasopharyngeal carcinomas (22, 24–26).